Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review

Stem Cell Research & Therapy

Burhan Abdullah Zaman¹  Raheleh Hazrati²  Meysam Mohammadi Khah³  Lakshmi Thangavelu⁴  Sima Marzban⁵  Samin Shokravi⁵  Vitaliy Borisov⁶  Firoozeh Niazvand⁷  Amir Zamani⁸  Armin Sohrabi⁹ 

[1] Basic Sciences Department, College of Pharmacy, University of Duhok;Department of Medicinal Chemistry, Pharmacy Faculty, Tabriz University of Medical Sciences;Department of Oral and Maxillofacial Surgery, School of Dentistry, Shahid Beheshti University of Medical Sciences;Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Science, Saveetha University;Department of Research and Academic Affairs, Larkin Community Hospital;I.M. Sechenov First Moscow State Medical University (Sechenov University);School of Medicine, Abadan University of Medical Sciences;Stem Cell Research Center, Tabriz University of Medical Sciences;Student Research Committee, Tabriz University of Medical Sciences;

关键词: Mesenchymal stromal cell (MSCs);    Exosome;    Acute liver failure (ALF);    Immunomodulation;    Hepatocyte;   

DOI  :  10.1186/s13287-022-02825-z

来源: DOAJ

【 摘 要 】

Abstract Recently, mesenchymal stromal cells (MSCs) and their derivative exosome have become a promising approach in the context of liver diseases therapy, in particular, acute liver failure (ALF). In addition to their differentiation into hepatocytes in vivo, which is partially involved in liver regeneration, MSCs support liver regeneration as a result of their appreciated competencies, such as antiapoptotic, immunomodulatory, antifibrotic, and also antioxidant attributes. Further, MSCs-secreted molecules inspire hepatocyte proliferation in vivo, facilitating damaged tissue recovery in ALF. Given these properties, various MSCs-based approaches have evolved and resulted in encouraging outcomes in ALF animal models and also displayed safety and also modest efficacy in human studies, providing a new avenue for ALF therapy. Irrespective of MSCs-derived exosome, MSCs-based strategies in ALF include administration of native MSCs, genetically modified MSCs, pretreated MSCs, MSCs delivery using biomaterials, and also MSCs in combination with and other therapeutic molecules or modalities. Herein, we will deliver an overview regarding the therapeutic effects of the MSCs and their exosomes in ALF. As well, we will discuss recent progress in preclinical and clinical studies and current challenges in MSCs-based therapies in ALF, with a special focus on in vivo reports.

【 授权许可】

Unknown